IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:

WHARTON, David Peter

Examiner:

To be determined

Serial No.

To be determined

Group Art Unit:

To be determined

Filed:

24-Mar-2006

Docket No.

59750-012000/US

Title:

MEDICATION HOLDER

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Date of Mailing: March 24, 2006

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 CFR 1.8 on the date indicated, and addressed to MAIL STOP: IDS, Commissioner for Patents, Post Office Box 1450, Alexandria, Virginia 22313-1450.

INFORMATION DISCLOSURE STATEMENT [37 C.F.R. § 1.56]

MAIL STOP: IDS

Commissioner for Patents Post Office Box 1450 Alexandria, Virginia 22313-1450

Sir/Madam:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicant brings the references listed on the attached Form PTO-1449 to the examiner's attention. 37 C.F.R. § 1.56. Do not construe the filing of this information disclosure statement as a representation that applicant has made a search (37 C.F.R. § 1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. We enclose copies of any cited foreign documents. Copies of the U.S. references are not enclosed.

This Information Disclosure Statement is being submitted:

\boxtimes	1.			ee months of the filing date of a national application other than a					
		conti	nued	prosecution application under 37 C.F.R. § 1.53(d), or within three					
		mon	ths of	the date of entry of the national stage as set forth in 37 C.F.R.					
		§ 1.4	91 in	an international application; or before the mailing date of a first					
		Offic	ce acti	ion on the merits, and therefore, Applicant believes no fee is					
		requ							
	2.	Afte	r the p	period specified in paragraph (1) above of this section, but before the					
				ate of either a final action under 37 C.F.R. § 1.113, or a notice of					
				under 37 C.F.R. § 1.311, whichever occurs first, and is					
			companied by either:						
		a.	A sta	atement that:					
			(i)	Each item of information contained in the information disclosure					
				statement was cited in a communication from a foreign patent					
				office in a counterpart foreign application not more than three					
				months before the filing of the information disclosure statement; or					
			(ii)	No item of information contained in the information disclosure					
			\ /	statement was cited in a communication from a foreign patent					
				office in a counterpart foreign application, and, to the knowledge					
				of the person signing the statement after making reasonable					
				inquiry, no item of information contained in the information					
				disclosure statement was known to any individual designated in 37					
				C.F.R. § 1.56(c) more than three months before the filing of the					
				information disclosure statement;					
		b.	The	e fee for filing an Information Disclosure Statement under 37 C.F.R. §					

1.17(p) is \$180.00.

pa a.	•	of the issue fee and is accompanied by: atement that:
a.	. A sta	itement that:
		winent mat.
	(i) (ii)	Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months before the filing of the information disclosure statement; or No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months before the filing of the information disclosure statement;
] 1		etition requesting consideration of the information disclosure tement; and
]	c. The	e petition fee set forth in 37 C.F.R. § 1.17(i).

Applicant would appreciate the examiner initialing and signing a copy of attached Form PTO-1449 indicating that he or she considered the information and made the information of record.

If the transmittal letter is separated from this document and the PTO determines that an extension or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-2638.

Serial No. To be determined

10157334ATENT Docket No. 59750-012000/US

IAP20 Rec'd PCT/PTO 24 MAR 2006

Authorization is hereby given to charge any fees due, or credit any overpayment of fees, to Deposit Account No. 50-2638.

Respectfully submitted,

Reg. No. 54,103

Date: March 24, 2006

Customer Number 33717 GREENBERG TRAURIG, LLP 2450 Colorado Avenue, Suite 400E Santa Monica, CA 90404

Phone: (310) 586-7700 Fax: (310) 586-7800

E-mail: laipmail@gtlaw.com

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 144	9A/PTO		Соп	plete if Knows		
	INFORMATION DISCLOSURE			Application Number	To be determine 1) 4 4		
				Filing Date	24-Mar-2006		
STATEMENT BY APPLICANT				First Named Inventor	To be determined		
	(Use as many sh	eets as r	necessary)	Art Unit	To be determined		
	·			Examiner Name	To be determined		
Sheet	1 of		3	Attorney Docket Number	59750-012000/US		

			U. S. PATENT		
Examiner Initials	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SD/		US - 4,130,116 A	12-19-1978	CAVAZZA	9
-		US - 5,497,764 A	03-12-1996	RITSON ET AL.	0000
		US - 5,522,378 A	06-04-1996	RITSON ET AL.	
		US - 5,622,162 A	04-22-1997	JOHANSSON ET AL.	3500
7\$D/	ļ — —	US - 5,755,218 A	05-26-1998	JOHANSSON ET AL	0000
, & 32 ,					
	1				
	 				
	┼				
	-				
	+				
	+-				
	 				
				NT DOCUMENTS	1

		FOREIG	N PATENT DOCL	JMENTS		
Examiner Initials	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
/SD/		Country Code ³ Number - Kind Code ⁵ (If known) BE 905189 A	01-29-1987	GLAXO GROUP LTD	*	Y
/3D/ I		CA 2379137 A1		PHARMACEUTICAL DISCOVERY CORPORATION		Y
	-	DE 4028387 A	03-12-1992	BECHTER	X	Y
/SD/		EP 1386630 A1	02-04-2004	CHIESI FARMACEUTICI SPA	* *	

04/22/2009 Date /Steven Douglas/ Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to Inis collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231 3-1450.

IAPZORES'S PCTATO 24 MAR 2006

PTO/SB/08a (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449			Com	plete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	To be determined 2 1 3 5 4			
			Filing Date	24-Mar-2006			
	SIAIEMEN) I AFT	LICAN	First Named Inventor	To be determined To be determined		
	(Use as many she	ets as n	ecessary)	Art Unit			
	•			Examiner Name	To be determined		
Sheet	2	of	3	Attorney Docket Number	59750-012000/US		

	Cita	Danis at Number	U. S. PATI		Nam	e of Patentee or	Pa	ages, Columns, Lines, Where	Ì
xaminer Initials	Cite No. ¹	Document Number	MM-DD-YYY		Applicar	t of Cited Document	Re	elevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (if known)}							
					- <u>-</u>				
							-		
				-					
	-								
	<u> </u>		FOREIGN F	ATENI	DOCL	MENTS			
			FUREIGN					D Octobre Lines	
Examiner	Cite	Foreign Patent Do	cument		tion Date D-YYYY	Name of Patentee of Applicant of Cited Doo	ument	Pages, Columns, Lines, Where Relevant Passages	T ⁶
Initials	No.1	Country Code ³ Number (Kind Code ⁵ (_	DURA PHARMACEUTIC		or Relevant Figures Appear	+-	
/SD/		WO 1995/028192 A1		10-26-199	5 	INC. INHALE THERAPEUTIC			+-
		WO 2001/000263 A2		01-04-200		SYSTEMS		8	+-
		WO 2002/004043 A2		01-17-200		VAPOTRONICS INC. E			+
/SD/		WO 2003/095010 A2		11-20-200)3	ORIEL THERAPEUTICS	INC.		-

04/22/2009 Date /Steven Douglas/ Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Including copy of this form with next communication to applicant. 1 Applicants unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at copy of this form with next communication to applicant. 1 Applicants unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at the www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under will be supposed to the patent document is to place a check mark here if English language Translation is attached.

VVIPU Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the complete data and the process of the pro

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231 3-1450.

IAP20 Rec'd PCT/PTO 24 MAR 2006

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449	A/PTO			Com	plete if Known		
					Application Number	To be determined 2 1 3 3 4		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	24-Mar-2006			
	STATEMENT BY APPLICANT				First Named Inventor	To be determined		
	(Use as many she	ets as r	necessary)		Art Unit	To be determined		
	·				Examiner Name	To be determined		
Sheet	3	of 3		3	Attorney Docket Number	59750-012000/US		

xaminer	Cite	Document Number	Publication	TENT DO	Nam	e of Patentee or	Pa	ages, Columns, Lines, Where elevant Passages or Relevant	
Initials	Cite No.1	Number-Kind Code ² (if known)	MM-DD-	m	Applicar	at of Cited Document	Relevant Passages or Relevant Figures Appear		
									_
							 		
	-								
							<u> </u>		_
	<u> </u>								=
			FOREIGN	PATEN	DOCU	MEN IS			T
Examiner	Cite No.1	Foreign Patent		Publica MM-Di	tion Date	Name of Patentee of Applicant of Cited Doo	Cited Desumost Minere Relevant Passaucs		
Initials	NO.	Country Code ³ Number 4 Kind Coo			GLAXO GROUP LIMITE	or Relevant Figures Appear		†	
/SD/		WO 00/18455 A1	04-06-200		AL			\dagger	
									Ť
									T

Date 04/22/2009 /Steven Douglas/ Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicants unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

WIPO standard \$1.16 if possible, 6 Applicant is to prace a check mark nere if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to This collection of information. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this submitting the completed application.

1.2. **Completed**

1.2. **Completed**

1.2. **Completed**

1.2. **Completed**

1.3. **Completed**

1.4. **Completed**

1.4. **Completed**

1.4. **Completed**

1.5. **Completed**

1.6. **Completed**

1.6. **Completed**

1.7. **Completed**

1.7. **Completed**

1.7. **Completed**

1.7. **Completed**

1.7. **Completed**

1.8. **Completed**

1.9. **Complete

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231 3-1450.